KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Net Cash Flow (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Net Cash Flow data on record, last reported at -$8.0 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 257.38% year-over-year to -$8.0 million; the TTM value through Dec 2025 reached -$16.1 million, down 167.23%, while the annual FY2025 figure was -$16.1 million, 167.23% down from the prior year.
  • Net Cash Flow reached -$8.0 million in Q4 2025 per RIGL's latest filing, down from -$4.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $64.8 million in Q2 2021 and bottomed at -$54.4 million in Q3 2021.
  • Average Net Cash Flow over 5 years is $513200.0, with a median of -$438000.0 recorded in 2022.
  • The widest YoY moves for Net Cash Flow: up 839.79% in 2021, down 55630.61% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$11.5 million in 2021, then skyrocketed by 53.04% to -$5.4 million in 2022, then crashed by 133.55% to -$12.6 million in 2023, then surged by 140.02% to $5.1 million in 2024, then tumbled by 257.38% to -$8.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$8.0 million in Q4 2025, -$4.9 million in Q3 2025, and $7.7 million in Q2 2025.